The
polyglutamine (
polyQ) diseases are a group of inherited
neurodegenerative diseases that include
Huntington's disease, various
spinocerebellar ataxias,
spinal and bulbar muscular atrophy, and
dentatorubral pallidoluysian atrophy. They are caused by the abnormal expansion of a CAG repeat coding for the
polyQ stretch in the causative gene of each disease. The expanded
polyQ stretches trigger abnormal β-sheet conformational transition and oligomerization followed by aggregation of the
polyQ proteins in the affected neurons, leading to neuronal toxicity and neurodegeneration. Disease-modifying
therapies that attenuate both symptoms and molecular pathogenesis of
polyQ diseases remain an unmet clinical need. Here we identified
arginine, a chemical chaperone that facilitates proper protein folding, as a novel compound that targets the upstream processes of
polyQ protein aggregation by stabilizing the
polyQ protein conformation. We first screened representative chemical chaperones using an in vitro
polyQ aggregation assay, and identified
arginine as a potent
polyQ aggregation inhibitor. Our in vitro and cellular assays revealed that
arginine exerts its anti-aggregation property by inhibiting the toxic β-sheet conformational transition and oligomerization of
polyQ proteins before the formation of insoluble aggregates.
Arginine exhibited
therapeutic effects on neurological symptoms and
protein aggregation pathology in Caenorhabditis elegans, Drosophila, and two different mouse models of
polyQ diseases.
Arginine was also effective in a
polyQ mouse model when administered after symptom onset. As
arginine has been safely used for
urea cycle defects and for
mitochondrial myopathy,
encephalopathy,
lactic acid and
stroke syndrome patients, and efficiently crosses the blood-brain barrier, a
drug-repositioning approach for
arginine would enable prompt clinical application as a promising disease-modifier
drug for the
polyQ diseases.